The expert committee of the World Health Organization on classification of calcium antagonists: the viewpoint of the raporteur.

作者信息

Vanhoutte P M

出版信息

Am J Cardiol. 1987 Jan 23;59(2):3A-8A. doi: 10.1016/0002-9149(87)90169-x.

DOI:10.1016/0002-9149(87)90169-x

PMID:3812262

Abstract

摘要

相似文献

The expert committee of the World Health Organization on classification of calcium antagonists: the viewpoint of the raporteur.

Am J Cardiol. 1987 Jan 23;59(2):3A-8A. doi: 10.1016/0002-9149(87)90169-x.

Classification of calcium antagonists: proposal of the WHO Committee.

Pharmacol Res Commun. 1987 Mar;19(3):195-208. doi: 10.1016/0031-6989(87)90063-4.

Calcium antagonists--terminology, classification and comparison.

Arzneimittelforschung. 1985;35(1A):298-301.

[Classification of Ca antagonist by its chemical structure and characteristics of each derivative].

Nihon Rinsho. 1989 Aug;47(8):1719-27.

[Calcium channel blockers].

Arq Bras Cardiol. 1985 Jun;44(6):423-41.

Differentiation of calcium entry blockers into calcium channel blockers and calcium overload blockers.

Eur Neurol. 1986;25 Suppl 1:57-67. doi: 10.1159/000116061.

[Calcium antagonists, calcium entry blockers and calcium overload blockers; nomenclature and classification].

Ned Tijdschr Geneeskd. 1985 Apr 27;129(17):777-80.

[Calcium antagonists: current and future applications based on new evidence. Classification of calcium channel blockers].

Clin Calcium. 2010 Jan;20(1):24-30.

[Calcium channel blockers. Review and attempt at classification].

Rev Esp Cardiol. 1984 Sep-Oct;37(5):322-9.

How safe are calcium channel antagonists.

J Med Liban. 1995;43(3):120-1.

引用本文的文献

Calcium antagonists and ACE inhibitors. Effect on endothelium and vascular smooth muscle.

Drugs. 1993;46 Suppl 2:121-32. doi: 10.2165/00003495-199300462-00021.

Calcium channel antagonists, Part I: Fundamental properties: mechanisms, classification, sites of action.

Cardiovasc Drugs Ther. 1987 Dec;1(4):411-30. doi: 10.1007/BF02209083.

Flunarizine. A reappraisal of its pharmacological properties and therapeutic use in neurological disorders.

Drugs. 1989 Oct;38(4):481-99. doi: 10.2165/00003495-198938040-00002.

Protection by verapamil and nifedipine against ischaemia-induced loss of [3H]-(+)-PN 200-110 binding sites in the rat heart.

Naunyn Schmiedebergs Arch Pharmacol. 1990 Jan-Feb;341(1-2):137-42. doi: 10.1007/BF00195070.

Isradipine in hypertension.

Drugs. 1990;40 Suppl 2:10-4. doi: 10.2165/00003495-199000402-00005.

Idiopathic arterial calcification of infancy.

Calcif Tissue Int. 1991 Jan;48(1):1-6. doi: 10.1007/BF02555789.

Calcium-channel blockers and anaesthesia.

Can J Anaesth. 1991 Jan;38(1):75-89. doi: 10.1007/BF03009168.

Double-blind, randomized comparative study of the antihypertensive effect of nicardipine slow-release and nifedipine slow-release in hypertensive patients with coronary heart disease.

Cardiovasc Drugs Ther. 1991 Jun;5(3):647-54. doi: 10.1007/BF03029734.

Pharmacokinetic interactions with calcium channel antagonists (Part II).

Clin Pharmacokinet. 1991 Dec;21(6):448-60. doi: 10.2165/00003088-199121060-00005.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验